🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

US Corporate Board Director Changes SEC Filings — March 11, 2026

Across 36 SEC filings on USA Board Room Changes from March 11, 2026, a dominant theme is elevated C-suite and board turnover, with 18 departures/resignations/retirements (e.g., CFOs at Peloton, Bridger, Lattice; Presidents at ON Semi, Rayonier) versus 12 new appointments, signaling potential leadership transitions amid sector pressures. Neutral sentiment prevails in 70% of filings, with positive tones on experienced hires in AI/cyber (Mainz Biomed, Navitas, Spire) and mixed in cases like Atlassian's 10% workforce cut despite 25%+ cloud revenue growth. Period-over-period financial trends are sparse but highlight outliers: Tilly's Q4 FY2025 net sales +5.3% YoY to $155.1M with first profitable Q4 since FY2021 ($2.9M NI vs -$13.7M prior), contrasting FY2025 net loss improvement to -$17.5M from -$46.2M. No widespread insider trading data, but capital allocation via incentive plans (e.g., PSIX Phantom Units, Lifeway deferred cash) indicates retention focus. Portfolio-level pattern: Tech/semi sector sees 6/10 filings with finance/legal exits (Lattice CAO, ON Semi President), potentially bearish short-term but bullish on replacements like Navitas CFO. Upcoming catalysts include Mainz EGM (April 2026) and multiple 2026 AGMs.

36 high priority36 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 10, 2026

A wave of 18 DEF 14A proxy statements filed around March 10, 2026, primarily for virtual annual meetings in late April to early May 2026, highlights robust governance practices across US companies, with universal emphasis on director elections (avg board size 10-13, reductions in USB from 13 to 12 and Roadzen from 7 to 6), advisory say-on-pay votes, and auditor ratifications. Period-over-period trends show pockets of strength (M&T top-quartile 3.67% NIM FY2025, Chemours 56% YoY Opteon sales growth) amid mixed results (Chemours flat $5.8B sales YoY, -3% Adjusted EBITDA to $742M, net loss widened to $386M on $270M+ litigation). Banking sector leads with positive sentiment (USB, M&T) and new Tech/Cyber committees (effective Jan 1, 2026), signaling proactive risk management; tech/industrials emphasize board refreshment (e.g., IBM Ramon Laguarta addition, Whirlpool 5 new independents in 5 years). No widespread insider selling noted, but capital returns persist (Chemours $78M dividends). Portfolio implications: Governance enhancements support long-term stability, but litigation drags (Chemours) and neutral pay-vs-performance disclosures warrant monitoring say-on-pay outcomes for comp alignment risks.

18 high priority18 total filings
·daily

US Executive Officer Management Changes SEC — March 10, 2026

Across 34 filings in the USA Executive & Director Changes stream (19 new), the dominant theme is board and C-suite transitions, with 15 appointments/promotions (e.g., experienced CFOs at Equinix, Procore) signaling strategic strengthening, 14 neutral resignations/retirements (no disagreements noted), and 5 key CFO departures (Playtika, Xponential, SolarEdge) amid interim placements. Where financial enriched data is available (8/34 filings), revenue trends are robust—avg +37% YoY across Westrock Coffee (+39.8%), Shoulder Innovations (+50%), Virtuix (+41% 9m), Nature's Sunshine (+5.7%)—but margins mixed with compressions (Westrock gross -2%, Shoulder 76.5% vs 77%) and loss widening due to SG&A/R&D investments. Positive forward-looking signals include reaffirmed guidance (Procore FY26, SolarEdge Q1, Xponential FY26) and upbeat outlooks (Westrock 2026 EBITDA +29-44%, Nature's FY26 sales +4-7%). No insider trading patterns, but capital allocation favors retention via salary hikes (Citizens CEO +20%, Cross Country CAO to $340k) and RSU grants. Portfolio implication: Bullish for firms hiring top talent amid growth; monitor CFO churn in high-growth sectors for execution risks. Overall sentiment leans neutral-positive (18 positive/mixed, 14 neutral/negative), with healthcare/tech leading hires.

34 high priority34 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 10, 2026

Across 34 US SEC filings on board and executive changes dated March 10, 2026, a dominant theme is high turnover in C-suite finance roles, with 9 CFO/CAO/CRO resignations or transitions (e.g., Playtika, NextEra, Xponential, SolarEdge, Equinix) and 7 new appointments (e.g., Harvard Bioscience, Procore, Equinix), signaling potential strategic shifts amid sector pressures. Where financial enriched data is available (7 filings), revenue growth averages +37% YoY (Westrock +39.8%, Shoulder Innovations +50%, Virtuix +41% 9mths, Nature's Sunshine +5.7%), but profitability is mixed with net losses widening in 3/4 cases (Westrock net loss $90.4M vs $80.3M, Shoulder FY loss $40.4M vs $15.6M) and gross margins stable/slightly down (-20bps avg). Positive sentiments prevail in 10/34 filings (29%), driven by experienced hires like Equinix's Olivier Leonetti (30+ yrs exp) and ADM's Michael McMurray, while neutrals dominate resignations (no disagreements noted in 15 cases). Forward-looking guidance in 5 firms shows optimism (Westrock EBITDA +29-44%, Nature's sales +4-7%, Shoulder +31-37%), but CFO searches create near-term uncertainty. Portfolio implications include monitoring finance-heavy sectors (REITs, tech, energy) for execution risks, with board additions enhancing governance in growth firms.

34 high priority34 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 09, 2026

Across 32 DEF 14A proxy statements, the dominant theme is routine governance with 28/32 filings neutral in sentiment, focusing on director elections, auditor ratifications (e.g., PwC, Deloitte across multiple), and advisory say-on-pay votes, signaling stable board continuity amid no widespread executive pay controversies. A cluster of 13 closed-end funds (Flaherty & Crumrine, Western Asset) shows highly concentrated ownership via Cede & Co. (98-99.97%) and low director/officer holdings (<1%), indicating institutional dominance but limited insider alignment. Limited period-over-period data reveals outliers like Deluxe Corp's 10% YoY growth in Payments/Data segments (to 47% of revenue from 43%), +6% adjusted EBITDA, +10% adjusted EPS, and FCF exceeding $100M target early, reducing leverage to 3.2x; Citizens Financial Group reported top peer TSR in 2025 with $226.4B assets. Mixed sentiments in 4 filings highlight risks in SPACs (5th extension), biotechs (NeuroOne reverse split for Nasdaq compliance, Moleculin 129% dilution from warrants), tempering portfolio optimism. No insider trading activity or capital allocation changes (dividends/buybacks) disclosed across filings, with forward-looking catalysts centered on April 2026 annual meetings (15+ events). Overall, low materiality (avg 5.6/10) suggests muted near-term volatility, but monitor biotech/SPAC dilutions and governance votes for alpha.

32 high priority32 total filings
·daily

US Executive Officer Management Changes SEC — March 09, 2026

Across 34 SEC filings on USA Executive & Director Changes from March 9, 2026, the dominant theme is proactive board expansions and executive appointments (18 instances, e.g., Phillips 66 added 2 independent directors, FTI named experienced CFO Angela Nam), signaling strengthened governance amid growth phases, contrasted by 12 departures (7 planned retirements like West Pharma CEO Eric Green H2 2026, 5 sudden like Gulfport CEO John Reinhart). Positive sentiment prevails in 14/34 filings (41%), particularly biotech/pharma (Zevra revenue +351% YoY to $106.5M, Boundless R&D -26% YoY to $9.8M Q4), while mixed/neutral in energy transitions. Period trends show cost discipline (Boundless op ex -23% YoY Q4) and revenue surges (FTI FY25 $3.8B, Zevra Q4 +184% YoY), with reaffirmed guidance in West Pharma/Planet Fitness indicating stability. No widespread insider selling; equity grants/bonuses (e.g., Alpha Omega 220% CEO max bonus) reflect alignment. Sector patterns: Energy leadership churn (4/34 filings), biotech hiring for trials/growth. Implications: Bullish for continuity hires, monitor sudden exits for volatility; portfolio-level alpha in pharma turnarounds.

34 high priority34 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 09, 2026

The 34 filings in the 'USA Board Room Changes' stream reveal a surge in C-suite and board transitions, with 22 CEO/CFO/COO appointments or departures and 12 board additions/resignations, signaling strategic realignments amid growth phases for biotechs and energy firms. Positive sentiments dominate (14/34 filings), driven by experienced hires like FTI Consulting's Angela Nam (scaled revenues 3.5x at prior role) and Mesa Labs' Siddhartha Kadia ($2B business oversight), while mixed/neutral tones accompany sudden exits like Gulfport Energy's CEO Reinhart (materiality 9/10). Period-over-period trends show biotech outperformance: Zevra Therapeutics revenue +351% YoY to $106.5M, Boundless Bio expenses -19% FY YoY with $108M cash to H2 2028; energy firms reaffirm strategies post-changes. No widespread insider selling detected, but capital allocation stable with reaffirmed guidance (Planet Fitness, West Pharma). Portfolio-level pattern: 70% of high-materiality (7+/10) changes are positive/neutral, implying low disruption risk but watch for CEO searches in energy/consulting. Overall, bullish for hires enhancing execution in scaling firms, bearish for leadership vacuums in mature players.

34 high priority34 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 06, 2026

Across 25 DEF 14A proxy statements filed around March 6, 2026, for April 2026 annual meetings, dominant themes include standard proposals for director elections (all companies), advisory say-on-pay votes (24/25), and auditor ratifications for FY2026 (25/25), with heavy representation from financials/banks (9/25 filings). Period-over-period data highlights record performances in outliers like Unity Bancorp (ROE 18.07%, NIM 4.52%) and Kirby Corp (revenues +3% YoY to $3.4B, EPS +16% to $6.33), contrasted by cost controls (Mobix auditor fees -19.5% YoY) and pay hikes (Boeing CEO +28% to $23.6M amid -3.8% stock drop). Sentiment skews neutral (18/25), with positives in AGNC (559% TSR since IPO vs 264% S&P Financials) and Unity, mixed in high-materiality cases like Boeing, Mobix (Nasdaq reverse split), CDT Equity (80% dilution risk), and Kirby. Portfolio-level trends show margin stability or strength in performers, high insider ownership in Seaboard (74.5%), and capital allocation via dividends (AGNC $15B cumulative). Market implications favor monitoring governance votes for comp alignment amid M&A (Tri Pointe, DataSea) and Nasdaq risks, with alpha in undervalued outperformers pre-meeting catalysts.

25 high priority25 total filings
·daily

US Executive Officer Management Changes SEC — March 06, 2026

Across 49 SEC filings dated March 6, 2026, focused on USA executive and director changes, a surge in C-suite transitions dominates, with 18 CFO/CAO/accounting officer shifts (e.g., FTAI Aviation, GXO Logistics, PacBio), 15 board appointments/expansions (e.g., PROCEPT BioRobotics, Middleby, Korn Ferry), and 12 departures/resignations (e.g., BiomX CEO, Ashford Hospitality CFO, Planet 13 CAO), signaling portfolio-level leadership refresh amid neutral sentiment (70% neutral, 15% positive, 10% mixed/negative). No explicit YoY/QoQ financial trends emerge due to filing focus, but compensation enhancements in 8 firms (e.g., Workday CEO equity awards up to 547k PVUs, James River CEO incentives doubled to 150%/200%) indicate management retention efforts and conviction. Liberty Media ecosystem shows coordinated CLO transitions to advisor roles (3 filings), while small-caps like 374Water and Vicarious Surgical report terminations/salary cuts amid restructuring/delisting risks. Positive hires emphasize finance/audit expertise (e.g., GXO CFO with 30+ years), potentially bolstering margins/operations, but sudden exits raise governance flags. Implications: Bullish for firms adding proven talent (e.g., MIDD, KFY), bearish for abrupt CFO churn (avg materiality 7/10), with catalysts like annual meetings (May-Jun 2026) and transitions (Apr-Jan 2027) to monitor for stability.

49 high priority49 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 06, 2026

Across 49 SEC filings on March 6, 2026, focused on USA board room changes, the dominant theme is elevated C-suite turnover, particularly in finance roles with 15+ CFO/CAO transitions, appointments, or departures, amid neutral sentiment (avg materiality 6/10). Positive hires of experienced executives (e.g., ex-CFOs from Shockwave, Deloitte, Spirit AeroSystems) in 12 companies signal strategic refresh for growth/margins, while sudden terminations (e.g., Planet13 CAO, Midland CFO) raise stability concerns. No aggregate period-over-period financial trends disclosed (e.g., revenue YoY, margins QoQ absent), but compensation hikes (e.g., James River CEO STI to 150% base, Workday CEO 547k PVUs) and equity grants indicate management retention focus. Liberty ecosystem (3 filings) shows coordinated CLO transition to advisor role later 2026, neutral impact. Portfolio-level: Small/mid-caps dominate churn (30/49), suggesting governance evolution; watch Q2 2026 for post-transition execution as catalysts.

49 high priority49 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 05, 2026

Across 12 DEF 14A proxy statements filed around March 5, 2026, a dominant theme is seeking advisory approval on 2025 executive compensation packages, director elections, and auditor ratifications ahead of clustered April 2026 annual meetings, with virtual formats in 11/12 cases. Financial firms like BNY Mellon (178% TSR outperforming S&P Financials 2.5x, 18% annualized EPS growth 2022-2025), First Business Financial (235% 5yr TSR vs peer median 66%, 11% YoY deposit growth), and Publix (superior results with peer-low comp) highlight strong period-over-period performance justifying pay, contrasting neutral filings lacking metrics. Capital allocation shines in PPG Industries ($1.9B op cash flow, $790M buybacks or 3% shares, 54th consecutive dividend hike) amid flat 2% organic sales. Portfolio-level trends show 4/12 with bullish metrics (revenue/EPS/TSR outperformance), mixed in industrials, neutral elsewhere; high prior say-on-pay support (e.g., BNY 95%) signals low dissent risk. Market implications include potential stock boosts post high-vote approvals, governance enhancements via new directors (Publix +1 to 9), and watch for SPAC merger risks in Relativity. Overall, financial sector conviction high, supporting overweight amid 2026 catalysts.

12 high priority12 total filings
·daily

US Executive Officer Management Changes SEC — March 05, 2026

Across 34 SEC filings on US executive and director changes dated March 5, 2026, a dominant theme is proactive board refreshes and strategic leadership appointments, with 18 positive sentiment filings highlighting expertise in AI, growth, M&A, and operations, signaling confidence in scaling amid competitive markets. CFO/CAO transitions are prevalent (9 cases), including retirements (Cardinal Health, McKesson), departures to peers (Sysco's Cheung to McKesson), and promotions (GEO, Trulieve), with no major operational disruptions noted but smooth handovers emphasized. Where enriched data provides period trends, standout growth includes PACS Group's 2025 revenue +29.3% YoY to $5.29B and Sysco's FY2025 sales >$81B, alongside reaffirmed FY2026 guidance at high-end EPS $4.50-$4.60 despite CFO exit. Neutral sentiment dominates (16 filings) on routine changes, with few bearish signals like terminations without cause (Trulieve CAO) or role eliminations (Match COO). Portfolio-level patterns show healthcare/distribution sectors leading in C-suite stability via internal promotions, while tech/biotech adds AI/defense talent for innovation catalysts. Capital allocation leans toward retention via equity grants/RSUs (e.g., Invitation Homes $11.3M CEO LTIP, SentinelOne $18M CFO equity), with no dividend/buyback shifts but increased incentives tied to EBITDA/TSR. Implications favor long-term holders in refreshing boards, watch CFO handovers for earnings volatility.

34 high priority34 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 05, 2026

Across 34 US SEC filings dated March 5, 2026, focused on board room changes, a dominant theme is proactive board refreshments and C-suite transitions, with 18 positive sentiment announcements (e.g., expert director additions at AZZ, Janus, PacBio) signaling strategic enhancement amid growth strategies. Neutral sentiments prevail in 13 cases involving retirements/planned successions (e.g., Cardinal Health CAO retire Feb 2027, McKesson CFO May 2026), minimizing disruption, while 2 negative/mixed cases highlight risks (Match Group COO elimination, Sysco CFO to Fortune 10). Sparse but positive period trends include PACS revenue +29.3% YoY to $5.29B, Sysco FY25 sales >$81B with FY26 EPS guidance reaffirmed at high-end $4.50-$4.60, and WEBTOON 160M MAUs. Forward-looking catalysts cluster in Q2 2026 (multiple effective dates), with comp plans tying awards to EBITDA/ROIC/TSR (e.g., Invitation Homes NOI CAGR targets to 2028). Portfolio-level: High talent mobility (e.g., Kenny Cheung Sysco to McKesson), board independence rising (AZZ 7/8 independent), implying sector confidence but CFO/CAO churn (9 instances) warrants monitoring for execution risks. Actionable: Favor healthcare/tech with deep benches (Delta, SentinelOne), avoid abrupt terminations (Trulieve, Match).

34 high priority34 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 04, 2026

Across 21 DEF 14A proxy statements filed around March 4, 2026, the dominant theme is preparation for Q2 2026 annual/special meetings focused on director elections (one-year or staggered terms), advisory say-on-pay votes, and auditor ratifications, reflecting stable governance amid no reported financial declines or period-over-period metric deteriorations. High board independence prevails (e.g., 11/12 at Texas Instruments, 100% independent committees at Xperi), with >75% attendance rates standard (Select Medical 8 meetings FY2025, iPower 3 meetings +5 consents YE6/30/25), signaling strong alignment. Closed-end funds (8/21, Nuveen cluster) cluster elections on April 16 with neutral sentiment/low materiality (5-6/10); operating companies show governance tweaks like declassification (Select Medical), CEO transitions (A.O. Smith), and combined Chair/CEO (CenterPoint). Mixed sentiments in Celanese (strategic transformation post-Micromax divestiture) and Goldenstone SPAC (extension vote risks liquidation, trust $5.77M at 12/31/25 ~$13.03/share redemption vs $11.51 close). No insider trading, capital allocation, or YoY financial trends reported, but upcoming comp votes and pay-vs-performance disclosures (MYR, H.B. Fuller XBRL PEO/NEO adjustments FY21-25) offer alignment insights. Portfolio implications: monitor April meeting outcomes for say-on-pay pass rates as comp conviction proxy; SPAC/special proposals flag distress opportunities.

21 high priority21 total filings
·daily

US Executive Officer Management Changes SEC — March 04, 2026

Across 29 US SEC filings on executive and director changes from March 4, 2026, overarching themes include routine retirements and appointments (17 neutral), strategic hires in AI/tech/biotech (positive sentiment in 6), and concerning departures (negative in 4), with mixed financial updates in high-materiality filings like BillionToOne's 100% FY2025 revenue growth and National Presto's 29.7% sales rise offset by 20.2% earnings drop. Period-over-period trends reveal strong growth outliers (BillionToOne +113% Q4 revenue YoY, oncology +735%) amid margin expansions (e.g., 68% FY gross margin vs 53% prior), but pockets of decline like Clinical Trial revenues -18% YoY. Positive capital allocation signals include National Presto's unbroken 82-year dividend ($1.00/share, record Mar 9) and Alnylam's CEO performance award tied to 54-146% stock price upside by 2029. Portfolio-level patterns show financials/banks with board reductions/resignations (WesBanco -4 directors, MVB governance dispute), signaling potential governance risks, while biotech/health firms emphasize experienced hires for pivots (Tivic CEO, FactSet AI roles). Market implications favor innovation-driven leadership continuity for alpha, with watch for succession voids in finance.

29 high priority29 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 04, 2026

Across 29 US SEC filings on boardroom changes from March 4, 2026, a surge in C-suite and director transitions highlights proactive succession planning in tech/AI (FactSet), biotech/health (Tivic, BillionToOne, RemSleep), and packaging (Crown), contrasted by retirements and resignations in financials (AmeriServ, Johnson Outdoors, MVB, WesBanco). Period-over-period trends show robust growth outliers like BillionToOne's Q4 2025 revenue +113% YoY ($96.1M) and FY +100% ($305.1M) with gross margins expanding to 71% Q4/68% FY from 57%/53%, and National Presto's defense sales +42.9% YoY ($121.9M increase), though offset by housewares declines -7% and net earnings -20.2%. Forward-looking catalysts include raised 2026 revenue guidance at BillionToOne ($430-445M, +41-46%), Alnylam's stock price vesting targets ($500-800 by late 2029), and dividend record dates (Presto March 9). Capital allocation leans toward equity incentives (Alnylam $18M award, RemSleep 7% equity) vs. modest dividends (Presto $1.00/share). Portfolio implications: Bullish for AI/biotech pivots amid experienced hires, bearish governance risks in financials; monitor Q1 earnings for transition impacts.

29 high priority29 total filings
·daily

US Executive Officer Management Changes SEC — March 03, 2026

Across 32 filings on US executive and director changes dated March 3, 2026, dominant themes include orderly planned retirements and successions (e.g., Cigna, Energy Fuels, Nucor), experienced appointments (e.g., Wyndham CFO, Massimo CFO, Protagenic President), and compensatory updates (severance plans, bonuses, LTIPs in 12 firms), with 14 positive, 12 neutral, and 4 mixed sentiments signaling management stability amid sector diversity from banking to biotech and energy. Period-over-period trends highlight outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, Byrna's 84% CAGR revenue growth since 2019, and CigNA's revenue expansion from $18B to $275B (+1428% over 17 years) with +750% TSR, contrasting Prairie Operating's leadership vacuum. No widespread insider selling noted, but capital allocation via debt repayment (Black Rock reduced term loan by $30.1M) and equity grants (e.g., Target Hospitality PSUs up to 200% vesting) supports shareholder alignment. Forward-looking reaffirmations (Wyndham, Cigna 2026 outlooks) and guidance (Black Rock FY2026 revenue $255-257M, EBITDA $33.5-34.5M) indicate confidence, though interim CEOs (Prairie) flag transition risks. Portfolio implications favor long-term holders in growth firms with smooth handovers, monitoring oil/gas for leadership gaps.

32 high priority32 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 03, 2026

Across 31 SEC filings on USA Board Room Changes from March 3, 2026, a dominant theme is orderly leadership transitions with 12 CEO/President/CFO appointments or promotions highlighting experienced hires (e.g., Byrna, Wyndham, Cigna, Massimo), 10 retirements/resignations without disagreements (e.g., Nucor, PCA, Northpointe), and 5 interim roles signaling searches (Prairie Operating). Positive sentiment prevails in 14 filings (45%), driven by growth legacies like Cigna's 750% TSR and Byrna's 84% CAGR revenue growth from $0.25M to $118M, while mixed/neutral tones in 15 reflect change-of-control (Slam Corp) or vague details (ACRG). Period trends show outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, but FY net loss widened 130.1%; Wyndham boasts 20 straight quarters of net room growth. No broad insider selling/buying patterns, but capital allocation via equity grants (e.g., Protagenic 1% dilution, Target Hospitality PSUs) and severance enhancements (Group 1, Simmons) indicate retention focus amid no major guidance cuts—Wyndham/Cigna reaffirmed 2026 outlooks. Portfolio implications favor monitoring healthcare/energy for succession stability boosting TSR, while small-caps risk interim leadership gaps.

31 high priority31 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 02, 2026

Crane Harbor Acquisition Corp. (CHAC), the sole filing in this Executive Compensation Insights stream, details a high-materiality (9/10) SPAC business combination with Xanadu Quantum Technologies Inc. via NewCo, with neutral sentiment and no disclosed prior period financial performance, metrics, or executive compensation specifics. The DEFM14A proxy seeks shareholder approval at an extraordinary general meeting on March 19, 2026, for the merger under a November 3, 2025 agreement, including a continuance from Cayman Islands to Ontario and massive share issuances (515M Class A Multiple Voting Shares, 79M Class B Subordinate Voting Shares). PIPE financing at $10.00 per share from Crane Harbor Sponsor affiliates underscores sponsor commitment amid no YoY/QoQ trends available. This positions CHAC for entry into quantum technologies, a high-growth sector, but highlights typical SPAC risks like dilution and approval dependency. No insider trading, capital allocation details (e.g., dividends/buybacks), or forward-looking financial guidance beyond transaction timelines are enriched, limiting period comparisons but flagging the March 19 catalyst as pivotal for market implications. Overall, the filing signals concentrated event-driven opportunity in quantum computing via SPAC de-SPACing.

1 high priority1 total filings
·daily

US Executive Officer Management Changes SEC — March 02, 2026

Across 53 SEC filings on US executive and director changes from March 2, 2026 (covering events Feb-Mar 2026), the dominant theme is a surge in leadership transitions with 28 appointments/promotions (e.g., experienced CFOs/CEOs in Eaton, Asana, L3Harris) signaling continuity and growth conviction, contrasted by 19 resignations/retirements (e.g., planned in Civista, chaotic in BiomX/TON Strategy) and 6 restructurings/comp changes. Period-over-period trends show robust revenue growth in reporting firms: MongoDB Q4 FY2026 +27% YoY to $695.1M, Atlas +29% YoY; Dave Inc Q4 2025 +62% YoY to $163.7M, FY +60% YoY; Great Elm Q4 NII +50% QoQ to $0.31/share, though NAV -20% QoQ. Positive sentiment in 14/53 filings (tech/finance hires), negative/mixed in 9 (biotech distress), neutral dominant. Portfolio-level patterns: Banking sector orderly CEO successions (Civista, First Bancorp), tech internal promotions amid strong growth (Asana CFO, MongoDB CCO), biotech high turnover risks. Market implications: Bullish for stable transitions with growth backdrops (e.g., Eaton $27.4B 2025 rev), bearish for governance disputes (TON Strategy CEO firing with self-dealing claims); alpha in pre-IPO catalysts (L3Harris Missile Solutions) and buyback hikes (Dave $300M authorization).

53 high priority53 total filings
← All geographies